Takeda Pharmaceutical (TAK) Income towards Parent Company (2017 - 2026)

Takeda Pharmaceutical's Income towards Parent Company history runs 10 years deep, the most recent figure standing at -$2.3 billion for Q1 2026.

• On a quarterly basis, Income towards Parent Company fell 388.62% year-over-year to -$2.3 billion in Q1 2026; TTM through Mar 2026 was -$2.6 billion, a 222.16% decrease from a year earlier, with the FY2026 full-year figure at -$1.0 billion, down 242.88% from the prior year.
• Income towards Parent Company rose to -$2.3 billion in Q1 2026 per TAK's latest filing, from -$2.4 billion in the prior quarter.
• Across five years, Income towards Parent Company topped out at $2.0 billion in Q3 2023 and bottomed at -$2.4 billion in Q4 2025.
• The 5-year median for Income towards Parent Company is $642.4 million (2024), against an average of $341.4 million.
• Across the five-year window, Income towards Parent Company jumped 912.2% in 2023 and tumbled 422.64% in 2024, its largest moves.
• Year by year, Income towards Parent Company stood at $843.2 million in 2022, then plunged by 75.05% to $210.4 million in 2023, then tumbled by 422.64% to -$678.8 million in 2024, then sank by 252.74% to -$2.4 billion in 2025, then climbed by 1.88% to -$2.3 billion in 2026.
• Per Business Quant, the three latest TAK Income towards Parent Company figures stand at -$2.3 billion (Q1 2026), -$2.4 billion (Q4 2025), and $1.5 billion (Q3 2025).